ASP 8062

Drug Profile

ASP 8062

Alternative Names: ASP8062

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class
  • Mechanism of Action GABA B receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibromyalgia

Most Recent Events

  • 20 Jun 2017 Phase-I clinical trials in Fibromyalgia (In volunteers) in Japan (PO) (NCT03183739)
  • 14 Jun 2017 Astellas Pharma plans a phase I trial in Healthy volunteers(NCT03183739)
  • 08 May 2017 Astellas Pharma initiates a phase II trial in Fibromyalgia in USA (NCT03092726)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top